#Single-use Bioprocessing Market Size

[insightfulblogz]

Single-use Bioprocessing Market Outlook, Size, Growth, Price, Latest Trends & Industry Forecast 2032

Single-use Bioprocessing 2024

Single-use bioprocessing is a modern innovation that is transforming the landscape of pharmaceutical manufacturing and biotechnological production. Traditionally, bioprocessing involves the use of reusable equipment such as bioreactors and filtration systems, which require extensive cleaning and sterilization between uses. However, the advent of single-use bioprocessing has introduced an alternative that simplifies and accelerates the manufacturing process, reducing the need for cleaning, sanitization, and validation. This shift toward disposable systems has brought substantial efficiency gains, cost savings, and reduced time to market for pharmaceutical products.

Single-use Bioprocessing Market was estimated at USD 27.99 billion in 2023 and is expected to reach USD 108.19 billion by 2032 with a growing CAGR of 16.21% during the forecast period of 2024-2032.

Benefits of Single-Use Bioprocessing

Single-use bioprocessing offers several key advantages over traditional, reusable systems. One of the primary benefits is the reduction in cross-contamination risks, as disposable equipment is used for a single batch and then discarded. This eliminates the labor-intensive cleaning processes required for multi-use systems, lowering operational costs and reducing the potential for human error during the cleaning and sterilization procedures.

The flexibility offered by single-use systems is another significant advantage. These systems can be rapidly deployed, allowing manufacturers to scale production up or down with ease depending on demand. Unlike stainless-steel equipment, which requires significant time and resources for assembly, single-use systems can be set up and replaced quickly. This flexibility is particularly beneficial for small-scale, high-mix production environments or when producing rare or specialty drugs.

Furthermore, single-use bioprocessing systems offer significant advantages in terms of reducing the environmental impact of pharmaceutical production. Traditional systems often require large quantities of water, detergents, and chemicals for cleaning. In contrast, the disposable nature of single-use components means that fewer cleaning agents and less water are needed, leading to a more sustainable process.

Applications in Biopharmaceutical Manufacturing

In biopharmaceutical manufacturing, single-use systems have become crucial for the production of biologics, vaccines, and gene therapies. These therapies often require precision in every step of the manufacturing process, from cell culture to protein purification. With single-use bioreactors, manufacturers can streamline the cell culture process, improving cell growth and product yield while reducing contamination risks. As biologics become more prevalent, the demand for such systems has grown, further driving the need for single-use technologies in production lines.

In addition to cell culture, single-use bioprocessing is also widely used for filtration, mixing, and storage applications. Filtration systems, for example, are critical in the separation of proteins, viruses, and other by-products from the final product. Single-use filters provide an efficient, contamination-free alternative to traditional reusable filtration equipment, further enhancing the production process.

The modularity of single-use systems also offers advantages in the flexibility of scaling up or down depending on the specific production needs. For companies looking to launch new drugs or therapies, single-use systems allow for easier setup and quicker production cycles. This ability to scale production with minimal investment in new equipment is a major reason why many biopharmaceutical companies are making the shift to single-use technologies.

Challenges and Limitations

While single-use bioprocessing offers many benefits, it is not without its challenges. One key concern is the management of waste. Given that single-use systems are disposed of after each use, this can lead to significant increases in the amount of plastic waste generated. Biopharmaceutical companies are actively seeking sustainable solutions, such as using biodegradable or recyclable materials in the design of disposable components to address this issue.

Another challenge is the upfront cost of transitioning from traditional systems to single-use technologies. While single-use components often result in cost savings over time, the initial investment in these technologies can be high. Companies may also need to invest in training staff and adapting their facilities to accommodate the new systems.

Despite these challenges, the overall benefits of single-use bioprocessing, particularly in terms of efficiency, scalability, and reduced risk of contamination, continue to drive adoption across the pharmaceutical industry.

The Future of Single-Use Bioprocessing

The future of single-use bioprocessing is bright, with continued innovation expected in areas such as system integration, automation, and sustainability. As the demand for biologics and personalized medicines grows, the need for more adaptable and efficient manufacturing processes will only increase. Single-use technologies are poised to meet these demands, providing manufacturers with the tools they need to stay competitive and responsive in an ever-evolving market.

In addition, advancements in materials science and engineering will likely lead to the development of more sustainable and cost-effective disposable components, helping to mitigate environmental concerns. The ongoing development of closed-system technologies, which help prevent contamination by minimizing human intervention, is another area of significant progress.

As the biopharmaceutical industry continues to evolve, single-use bioprocessing will undoubtedly play an increasingly critical role in shaping the future of drug manufacturing, offering solutions that meet both the demands of efficiency and sustainability.

Conclusion

Single-use bioprocessing is revolutionizing the pharmaceutical manufacturing landscape by offering a more efficient, cost-effective, and flexible approach to production. With growing applications in biologics, vaccines, and gene therapies, this technology is enabling faster, cleaner, and more scalable manufacturing processes. Despite some challenges, including waste management and upfront costs, the benefits of single-use systems are clear. As the industry moves toward more sustainable practices, the future of single-use bioprocessing looks increasingly promising, paving the way for innovations in drug production and healthcare delivery.

Get Free Sample Copy @ https://www.snsinsider.com/sample-request/3661

Contact Us:

Akash Anand – Head of Business Development & Strategy

info@snsinsider.com

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

About Us

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

[acumenblog]

Single-Use Bioprocessing Market CAGR Forecasted at 16.2% from 2023 to 2032

Acumen Research and Consulting has recently published a research report on the Single-Use Bioprocessing Market for the forecast period of 2023 – 2032, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Single-Use Bioprocessing Market offers an extensive analysis of how the postoperative pain therapeutics landscape would…

[marketsndata]

[marketreports-blog]

According to Nova One Advisor, the global single-use bioprocessing market size was estimated at USD 28.45 billion in 2023 and it is projected to increase USD 128.24 billion by 2033 with a CAGR of 16.25% from 2024 to 2033.

[mitalipingale]

https://sparktv.net/read-blog/39450_single-use-bioprocessing-sensors-and-probes-market-size-overview-share-and-forec.html

The Single Use Bioprocessing Sensors and Probes Market in 2023 is US$ 3.08 billion, and is expected to reach US$ 7.64 billion by 2031 at a CAGR of 12%.

[luckydige45]

According to Nova One Advisor, the global single-use bioprocessing probes & sensors market size was valued at USD 3.85 billion in 2023 and is anticipated to reach around USD 11.27 billion by 2033, growing at a CAGR of 11.34% from 2024 to 2033.

[sanpdr1994]

Single-use Bioprocessing Probes and Sensors Market to Witness Massive Growth, Emerging Technology Research Report by 2022-2032

According to a recent Future Market Insights report, the Single-use Bioprocessing Probes and Sensors Market is currently valued at US$ 2.4 Bn and is expected to reach US$ 9.8 Bn by the end of 2032, by growing at the CAGR of 13.8%. During the forecast period, the global market is expected to offer an absolute dollar opportunity of around US$ 7.1 Bn, with the pH Sensors likely to lead the market with a CAGR of 16.5%.

Continuous technological advancements and the increased use of machine learning, automation, and big data solutions in several applications is likely to boost the market growth. These analytical models aid in the prediction of errors and the improvement of medical procedure accuracy. Furthermore, the market is expected to grow due to development in supply chain facilities that use cost and time effective technology.

Download Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14802

pH Sensors are the most important segment in terms of Sensor type categorization, and they are predicted to remain competitive with a CAGR of 16.5% over the forecasted period. Rising product penetration and usage rates are responsible for a large amount of category growth. Furthermore, the Upstream segments dominate the workflow categorization and are predicted to increase at a CAGR of 13.9% throughout the forecasted period. This occurred as a result of the growing use of single-use bioreactors and media bags in the upstream manufacturing process.

Key Takeaways from the Market Study

Global Single-use Bioprocessing Probes and Sensors Market is expected to reach the valuation of US$ 9.8 Bn by 2032.

The global market is expected to grow at a CAGR of 8% as compared to historical growth of just 11.4%.

During the period between 2022 and 2032, the market is expected to offer an absolute dollar opportunity of US$ 7.1 Bn.

The pH Sensors segment dominates the global market and is likely to grow at a CAGR of 5%.

Among the Workflow types, Upstream workflow dominates the segment with the expected CAGR of 9% during the forecasted period.

The U.S. market contributes significantly in the global market with around 29% Revenue through this segment is expected to grow at a CAGR of 12% during the forecasted period.

Continuous technological advancements and the increased use of Machine Learning, AI, Automation, and big data solutions in a number of applications are expected to boost the global market. These analytical models aid in the prediction of errors and the improvement of medical procedure accuracy, comments a Future Market Insights analyst.

Competitive Landscape

Market players in single-use bioprocessing probes and sensors are pursuing numerous strategic initiatives such as OEM alliances, market expansion, and new product development with improved technological complexity to promote their organic revenue growth and market presence. They are developing partnerships with key OEMs to build their single-use plants.

The key developments in Global Single-use Bioprocessing Probes and Sensors Market are:  

In September 2020, Thermo Fisher Scientific inaugurated the new Bioprocessing Collaboration center in St. Louis to accelerate innovation and enhancing productivity of Biopharma companies.

In November 2021, Sartorius AG announced that it will expand its operation, production, innovation and storage facilities in France by investing 100 Mn Euros by 2025.

In March 2022, ABEC collaborated with EKF Life Science for expanding its Biomanufacturing operations in U.S. market.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Single-use Bioprocessing Probes and Sensors market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Sensor Type (pH Sensor, Oxygen Sensor, Pressure Sensors, Temperature Sensors, Conductivity Sensors, Flow Meters & Sensors, Other Sensor Types), Workflow (Upstream & Downstream), End-use (Biopharmaceutical Manufacturer, Labs & Academic/ Clinical Research Institutes) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Future Market Insights’ Domain Knowledge in Healthcare Division

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned Healthcare domain team at Future Market Insights helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analysed the Healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

[healthcaremarketanalysis]

Understanding Single-Use Bioprocessing Systems: Revolutionizing Biomanufacturing

Single-use bioprocessing systems have gained significant traction in the biopharmaceutical industry due to their flexibility, cost-effectiveness, and reduced environmental impact. These systems, which are typically made from plastic components, are designed for one-time use, streamlining processes and minimizing contamination risks. This blog explores the key benefits, applications, and challenges of single-use bioprocessing systems.

Download PDF Brochure

What Are Single-Use Bioprocessing Systems?

Single-use bioprocessing systems (SUBs) consist of pre-sterilized, disposable components used in biomanufacturing processes. Unlike traditional stainless steel systems, which require extensive cleaning and validation after each use, SUBs can be discarded after a single production cycle. This eliminates the need for cleaning and reduces downtime, allowing for faster turnover between production batches.

Key Benefits of Single-Use Bioprocessing Systems

1. Reduced Risk of Cross-Contamination

Single-use systems are pre-sterilized, meaning that the risk of product cross-contamination is greatly diminished. This is especially important for biopharmaceutical companies that deal with sensitive biological products, such as vaccines and monoclonal antibodies.

2. Cost-Effectiveness

With fewer cleaning and sterilization requirements, single-use systems reduce operating costs. Companies also save on water, energy, and cleaning chemicals, making SUBs an environmentally sustainable option. Additionally, they minimize the capital investment needed for traditional steel equipment.

3. Increased Flexibility and Scalability

Single-use systems can be easily scaled up or down to meet the demands of different production sizes. This flexibility makes them ideal for contract manufacturing organizations (CMOs) that may need to handle varying production volumes.

4. Faster Time to Market

With reduced downtime between production cycles, SUBs can accelerate the time it takes to bring new drugs or vaccines to market. This agility is critical in fast-paced sectors like biotechnology and pharmaceuticals.

Request Sample Pages

Applications of Single-Use Bioprocessing Systems

Single-use bioprocessing systems are widely used in upstream and downstream bioprocessing, particularly in:

Vaccine Manufacturing: The global demand for vaccines, including those for COVID-19, has increased the need for flexible, fast, and scalable production methods. Single-use systems offer a perfect solution by enabling rapid scale-up without the risk of contamination.

Monoclonal Antibody Production: As a major component in biologics, monoclonal antibodies are produced using mammalian cell cultures, a process that requires sterile environments. Single-use bioprocessing systems ensure sterile conditions throughout production.

Cell and Gene Therapy: Personalized medicines like cell and gene therapies rely on small-batch production, where traditional bioprocessing systems may be too cumbersome. Single-use systems provide a streamlined, cost-effective solution.

Challenges in Single-Use Bioprocessing Systems

Despite their advantages, single-use bioprocessing systems come with some challenges:

Plastic Waste: One of the most cited concerns is the generation of plastic waste, as these systems are discarded after each use. While they reduce the need for water and chemicals, companies are working on strategies to recycle or dispose of the waste responsibly.

Material Compatibility: Not all biopharmaceutical products are compatible with the plastic materials used in SUBs. In some cases, product leachables or extractables may pose a risk to product quality.

Capacity Limitations: For very large-scale production, stainless steel systems may still be the more suitable choice, as single-use systems are better suited to small- and medium-scale operations.

Future Outlook: The Growing Role of Single-Use Bioprocessing Systems

As the demand for biopharmaceuticals grows, single-use bioprocessing systems are expected to play an increasingly vital role. Continuous advancements in materials and technologies will address current challenges, including waste reduction and material compatibility. The integration of automation and digital tools within SUBs is another exciting area, promising even greater efficiency in biomanufacturing processes.

Conclusion

Single-use bioprocessing systems represent a transformative shift in the biomanufacturing industry. Their ability to reduce contamination risks, lower costs, and accelerate production timelines makes them indispensable in today’s fast-paced, innovation-driven market. While challenges remain, ongoing improvements are paving the way for broader adoption, ensuring that single-use systems continue to revolutionize bioprocessing in the years to come.

Content Source:

[credenceresearchdotblog]

GMP Cell Therapy Consumables Market is valued at approximately USD 24.04 million and is projected to grow at a compound annual growth rate (CAGR) of 27.90% over the forecast period, reaching around USD 172.15 million by 2032.The Good Manufacturing Practice (GMP) cell therapy consumables market is evolving as a crucial segment within the biotechnology and pharmaceutical industries. As the demand for innovative therapies rises, particularly in the field of regenerative medicine and immune-oncology, the need for specialized consumables that adhere to stringent quality and safety standards has surged. This article explores the dynamics, key trends, and future outlook of the GMP cell therapy consumables market.

Browse the full report https://www.credenceresearch.com/report/gmp-cell-therapy-consumables-market

Understanding GMP Cell Therapy Consumables

GMP cell therapy consumables refer to the materials and reagents used during the production of cell-based therapies, manufactured under rigorous GMP guidelines. These consumables include cell culture media, reagents, growth factors, cytokines, cryopreservation solutions, and single-use bioprocessing systems. Adherence to GMP standards ensures the safety, efficacy, and quality of the final therapeutic products, essential for regulatory approval and patient safety.

Market Drivers and Trends

1. Rising Demand for Cell-Based Therapies Cell therapy, encompassing autologous and allogeneic approaches, has emerged as a promising frontier in treating chronic diseases, genetic disorders, and cancers. The success of therapies like CAR-T cells has fueled investments in cell therapy research and commercialization. Consequently, the demand for high-quality consumables to support these therapies has grown exponentially.

2. Stringent Regulatory Landscape Global regulatory bodies, including the FDA and EMA, emphasize compliance with GMP guidelines during the development and manufacturing of cell therapies. Companies must source GMP-compliant consumables to meet these regulatory requirements, driving demand in the market.

3. Technological Advancements in Bioprocessing The development of innovative single-use systems and automation technologies has revolutionized cell therapy manufacturing. These advancements enhance scalability, reduce contamination risks, and improve process efficiency. The adoption of these technologies has increased the reliance on GMP-certified consumables.

4. Expanding Biopharmaceutical Manufacturing With the growing pipeline of cell and gene therapies, biopharmaceutical companies are expanding their manufacturing capacities. This expansion necessitates a steady supply of consumables to ensure uninterrupted production, further propelling market growth.

Key Players and Competitive Landscape

The GMP cell therapy consumables market is characterized by the presence of established players and emerging companies. Key players such as Thermo Fisher Scientific, Sartorius AG, Merck KGaA, and Lonza Group dominate the market. These companies invest heavily in R&D to develop innovative and GMP-compliant products.

Startups and smaller firms are also entering the market, offering niche solutions and fostering competition. Strategic collaborations, mergers, and acquisitions have become common strategies to gain a competitive edge.

Challenges in the Market

1. High Production Costs Manufacturing GMP-compliant consumables involves stringent quality control measures and certification processes, leading to high production costs. These expenses are often passed on to end-users, making cost management a critical challenge.

2. Supply Chain Complexities The global supply chain for GMP cell therapy consumables is highly intricate, involving multiple stakeholders and geographies. Disruptions in supply chains, as observed during the COVID-19 pandemic, can impact market growth.

3. Regulatory Hurdles While regulations are necessary to ensure quality, navigating complex regulatory landscapes across different countries can be a time-consuming and costly process for manufacturers.

Future Outlook

The GMP cell therapy consumables market is poised for significant growth in the coming years. According to industry reports, the market is expected to grow at a compound annual growth rate (CAGR) of over 15% between 2023 and 2030. This growth will be fueled by increasing adoption of cell-based therapies, advancements in bioprocessing technologies, and supportive government initiatives.

Key Player Analysis:

Thermo Fisher Scientific Inc.

Lonza Group

Merck KGaA

Corning Inc.

Sartorius AG

Danaher Corporation

Miltenyi Biotec

Stemcell Technologies Inc.

GE Healthcare

Takara Bio Inc.

Segmentation:

Based on Product Type:

Cell Culture Media

Cell Separation Tools

Bioreactors

Cryopreservation Products

Other Consumables

Based on Technology:

Manual Systems

Automated Systems

Based on End-User:

Biopharmaceutical Companies

Research Institutions

Contract Manufacturing Organizations (CMOs)

Based on Region:

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

South Africa

UAE

Saudi Arabia

Browse the full report https://www.credenceresearch.com/report/gmp-cell-therapy-consumables-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[luckydige45]

According to Nova One Advisor, the global single-use bioprocessing probes & sensors market size was valued at USD 3.85 billion in 2023 and is anticipated to reach around USD 11.27 billion by 2033, growing at a CAGR of 11.34% from 2024 to 2033.

[health-views-updates]

Cell & Gene Therapy Manufacturing Services Market | Size, Share, Analysis, Overview, Segments, Key Players, Industry Research Trends & Forecast Report 2024-2032

The global cell & gene therapy manufacturing services market revenue is set for extraordinary growth, with the market size valued at USD 11.4 billion in 2023 and projected to reach USD 70.7 billion by 2032. This represents a compound annual growth rate (CAGR) of 22.4% during the forecast period from 2024 to 2032. The demand for advanced therapies and innovative manufacturing solutions is driving the significant expansion of this market, which is expected to play a critical role in the future of healthcare.

Cell and gene therapies offer transformative potential to treat and cure a range of chronic and rare diseases, including genetic disorders, cancer, and autoimmune diseases. These therapies involve altering genetic material within a patient’s cells to treat or prevent diseases, presenting a cutting-edge approach to modern medicine.

Key Market Drivers

Rising Demand for Cell & Gene Therapies: The increasing prevalence of genetic disorders and chronic diseases is driving the demand for innovative cell and gene therapies. Treatments like CAR-T cell therapy, gene editing, and stem cell transplants are gaining traction due to their ability to offer long-lasting or curative solutions for previously untreatable conditions. As these therapies continue to evolve, the need for specialized manufacturing services is also growing rapidly.

Growing Investment in Biopharmaceutical R&D: Pharmaceutical companies and biotechnology firms are significantly increasing their investments in the development of cell and gene therapies. This has led to a surge in clinical trials, with a growing number of cell and gene therapies moving through the development pipeline. The need for efficient and scalable manufacturing services is becoming paramount as these therapies progress from clinical stages to commercialization.

Advancements in Manufacturing Technologies: The development of advanced manufacturing technologies, such as automation, 3D bioprinting, and artificial intelligence (AI), is revolutionizing the cell and gene therapy manufacturing process. These technologies are helping to streamline production, reduce costs, and ensure product consistency and quality. Moreover, innovations in bioprocessing and single-use technologies are enhancing scalability, enabling manufacturers to meet the growing demand for these therapies.

Regulatory Support and Approvals: The global regulatory landscape is evolving to accommodate the rapid growth of cell and gene therapies. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have implemented expedited approval pathways for advanced therapies, encouraging the development and commercialization of these innovative treatments. The increasing number of approved therapies is contributing to the rising demand for manufacturing services.

Outsourcing of Manufacturing Services: The complexity and high cost of manufacturing cell and gene therapies have led many biopharmaceutical companies to outsource their production needs to contract development and manufacturing organizations (CDMOs). CDMOs provide specialized expertise, state-of-the-art facilities, and scalable production capabilities, allowing companies to focus on research and development while ensuring the efficient and compliant production of therapies.

Request a Free Sample @ https://www.snsinsider.com/sample-request/1187 

Challenges and Opportunities

Despite the impressive growth potential, the cell and gene therapy manufacturing services market faces several challenges. These include the high cost of production, difficulties in scaling up manufacturing processes, and the need for stringent quality control. Additionally, the industry requires highly specialized talent and infrastructure to manage the complexities of these therapies.

However, these challenges also present opportunities for innovation. The development of more efficient, cost-effective manufacturing processes, along with advancements in automation and AI-driven technologies, is expected to address many of these barriers. The growing demand for specialized manufacturing services also opens the door for CDMOs and other service providers to expand their capabilities and capacity.

Regional Insights

North America holds the largest share of the cell and gene therapy manufacturing services market, driven by significant investments in biopharmaceutical R&D, a strong presence of leading biotech companies, and supportive regulatory frameworks. Europe is another major market, with growing research activities and government initiatives aimed at fostering the development of advanced therapies.

The Asia-Pacific region is expected to experience the highest growth rate over the forecast period, fueled by the expansion of healthcare infrastructure, rising investments in biotechnology, and increasing demand for innovative therapies in countries such as China, Japan, and India.

Future Outlook

As the field of cell and gene therapy continues to evolve, the demand for high-quality, scalable manufacturing services is expected to grow exponentially. The projected CAGR of 22.4% from 2024 to 2032 highlights the vast potential of the market, with innovations in manufacturing technologies and regulatory support paving the way for further advancements.

In conclusion, the cell and gene therapy manufacturing services market is entering a phase of rapid expansion, with a projected growth from USD 11.4 billion in 2023 to USD 70.7 billion by 2032. As the demand for these life-changing therapies rises, the market will play a critical role in shaping the future of healthcare, offering new hope for patients with previously untreatable conditions.

Other Trending Reports

Functional Endoscopic Sinus Surgery Market Growth

Artificial Intelligence in Healthcare Market Growth

Radiotherapy Market Growth

Nicotine Replacement Therapy Market Growth